Tag Archives: T1D

June, 2018

25 June
Boehringer Ingelheim and Lilly Announce Top-Line Phase 3 Data Results for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes

INGELHEIM, Germany and INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, …
Share

19 April
Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …
Share
17 April
Rates of New Diagnosed Cases of Type 1 and 2 Diabetes on the Rise Among Children, Teens

Rates of new diagnosed cases of type 1 and type 2 diabetes are increasing among youth in the United States, according to a report, Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012, published today in the New England Journal of Medicine. In the United States, 29.1 …
Share

28 September
FDA Approves Medtronic’s Automated Insulin Delivery Device for Type 1 Diabetes

The U.S. Food and Drug Administration today approved Medtronic’s MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes. The human pancreas naturally supplies …
Share
9 September
Lexicon’s T1D Drug Meets Primary Endpoint in Late-Stage Study

THE WOODLANDS, Texas, Sept. 9, 2016 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized …
Share

9 June
First T1D Patient Free from Insulin Therapy After Undergoing New Transplant Technique

MIAMI, June 9, 2016 /PRNewswire-USNewswire/ — A 41-year-old man who was diagnosed with type 1 diabetes at age 11 has become the first patient in Europe to discontinue insulin therapy after receiving a transplant of pancreatic islet cells using an innovative technique developed by the Diabetes Research Institute (DRI) at …
Share

12 February
New Staging Classification for Type 1 Diabetes Opens Door for Intervention

SEATTLE, Feb. 12, 2016 /PRNewswire/ — For most people, the onset of type 1 diabetes seems to occur suddenly, often resulting in a trip to the emergency room with life-threatening complications such as diabetic ketoacidosis (DKA). TrialNet is a worldwide leader in type 1 diabetes prevention research and one of the …
Share